Sebela Pharmaceuticals, Inc.

Sebela’s potassium-competitive acid blocker (P-CAB) tegoprazan demonstrated superior efficacy to a proton pump inhibitor (PPI) in a Phase III trial in patients with gastroesophageal reflux disease (GE

The US Food and Drug Administration eliminated the Risk Evaluation and Mitigation Strategy for the antipsychotic clozapine, closing the book on a program that was never fully implemented or enforced,

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre

The US Food and Drug Administration has resumed what had been a languishing effort to assess the risk of possible neuropsychiatric side effects from the use of polyethylene glycol 3350 for chronic con